Symbol="CYCN"
AssetType="Common Stock"
Name="Cyclerion Therapeutics Inc"
Description="Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts."
CIK="1755237"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="301 BINNEY STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="9221900"
EBITDA="-38396752"
PERatio="None"
PEGRatio="None"
BookValue="1.804"
DividendPerShare="0"
DividendYield="0"
EPS="-16.24"
RevenuePerShareTTM="0.42"
ProfitMargin="0"
OperatingMarginTTM="-42.05"
ReturnOnAssetsTTM="-0.829"
ReturnOnEquityTTM="-1.858"
RevenueTTM="914000"
GrossProfitTTM="-29749000"
DilutedEPSTTM="-16.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.141"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="17.43"
PriceToBookRatio="1.711"
EVToRevenue="0.517"
EVToEBITDA="0.529"
Beta="1.888"
num_52WeekHigh="25"
num_52WeekLow="3.636"
num_50DayMovingAverage="4.779"
num_200DayMovingAverage="10.2"
SharesOutstanding="2407800"
DividendDate="None"
ExDividendDate="None"
symbol="CYCN"
open="3.93"
high="3.93"
low="3.75"
price="3.83"
volume="4006.00"
latest_trading_day="2023-07-06"
previous_close="3.96"
change="-0.13"
change_percent="-3.3755%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="85"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="15"
Volume_recent_avg="214702"
Change_recent_avg="0.01"
Delta_recent_avg="0.18"
Variance_recent_avg="0.09"
Change_ratio_recent_avg="-0.99"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="15"
Aroon_momentum_negative="85"
image_negative_thumbnail_id_1="1165"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0199.jpeg"
image_negative_thumbnail_id_2="1143"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0176.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="584"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0015.jpeg"
image_positive_thumbnail_id_1="996"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0158.jpeg"
image_positive_thumbnail_id_2="636"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0072.jpeg"
image_professor_thumbnail_id_1="1171"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
image_professor_thumbnail_id_2="1179"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
